- alle zwei WochenErscheinungsrhythmus
- 1 h 08typische Länge
- 23. Okt.letzte Folge
Folgenzu den neuesten
Ep182: Andy Rachleff & Yung Lie on Creative Ways to Back Science
Andy Rachleff and Yung Lie, board chair and CEO of Damon Runyon Cancer Research Foundation, on creative ways to support science amid budget cuts.
Ep181: Claire Mazumdar on a Two-Pronged Attack Against Cancer
Claire Mazumdar, CEO of Boston-based Bicara Therapeutics, on developing a bifunctional antibody for head and neck cancer.
Ep180: John Rinn on Discovering Drugs Based on Long Non-Coding RNA
John Rinn, professor at the University of Colorado and co-founder of Lincswitch Therapeutics, on exploring long non-coding RNA.
Ep179: Ethan Weiss & Josh Lehrer on a New Idea for Cardiovascular Disease & Diabetes
Marea Therapeutics CEO Josh Lehrer and CSO Ethan Weiss on a new angle of attack against cardiovascular disease and diabetes.
Ep178: Peyton Greenside on ML-Guided Biologics Discovery
Peyton Greenside, co-founder and CEO of BigHat Biosciences, on machine-learning guided biologic drug discovery.
Ep177: Kevin Parker on Finding Cancer Drug Targets
Kevin Parker, CEO of Cartography Biosciences, on finding new cancer drug targets.
Ep176: David Roblin on Building a TechBio Company
David Roblin, CEO of London-based Relation Therapeutics, on building a techbio discovery company.
Ep175: Andy Scharenberg on in vivo CAR-T cell therapies
Andy Scharenberg, CEO of Seattle-based Umoja Biopharma, on developing in vivo CAR-T cell therapies.
Ep174: Najat Khan on the TechBio Movement
Najat Khan, chief R&D and chief commercial officer of Recursion, on using technology to improve drug discovery.
Ep173: Robert Blum on Building a Fully Integrated Biopharma For Muscle Disorders
Robert Blum, CEO of South San Francisco-based Cytokinetics, on building a fully integrated biopharma to treat muscle disorders.
Ep172: Mostafa Ronaghi on Studying Live Cells at Scale
Mostafa Ronaghi, co-founder and executive board member of Cellanome, on developing technology to look at live cells and cellular interactions at scale.
Ep171: Ram Aiyar on RNA Editing Medicines
Ram Aiyar, CEO of Cambridge, Mass.-based Korro Bio, on RNA editing medicines.
Ep170: David Schenkein on Investing in the Future of Biotech
David Schenkein, general partner at GV, on investing in the future of biotech.
Ep169: Kevin Fitzgerald on the Past & Future of RNAi Medicines
Alnylam Pharmaceuticals chief scientific officer Kevin Fitzgerald on the past, present & future of RNA interference medicines.
Ep168: Jonathan Bricker on How to Quit Smoking & Prevent Cancer
Jonathan Bricker, professor in the cancer prevention program at Fred Hutchinson Cancer Center, on how to quit smoking with help from tech and biotech tools.
Ep167: Leslie Williams on transfer RNA therapies
Leslie Williams, CEO of Boston-based hC Bioscience, on developing transfer RNA therapies.
Ep166: Chris Garcia on Engineering Protein Drugs for Cancer, Autoimmunity
Chris Garcia, professor at Stanford University and co-founder of several biotech startups, on using protein engineering to advance new treatments for cancer and autoimmune diseases.
Ep165: Zach Hornby on Tackling Cancer Drug Resistance
Zach Hornby, CEO of San Diego-based Boundless Bio, on tackling cancer drug resistance.
Ep164: Ted Love and Alan Anderson on Raising the Bar for Sickle Cell Disease Patients
Ted Love, chairman of BIO, and Dr. Alan Anderson, executive director of Sickle Forward, on how to improve quality of life for sickle cell disease patients around the world.
Ep163: Sarah Boyce on RNA Medicines for Muscle Diseases
Sarah Boyce, CEO of San Diego-based Avidity Biosciences, on RNA medicines for rare muscle diseases.
Ep162: Sean McClain on AI for Biologic Drug Discovery
Sean McClain, CEO of Absci, on using AI to speed up biologic drug discovery.
Ep161: Jeff Stein on a Long-Lasting Flu Drug
Jeff Stein, CEO of San Diego-based Cidara Therapeutics, on a long-lasting drug against flu.
Ep160: Abe Ceesay on Precision Neuroscience
Abe Ceesay, CEO of Boston-based Rapport Therapeutics, on a precision medicine approach to neuroscience drug discovery.
Ep159: Jimi Olaghere on Being Functionally Cured of Sickle Cell Disease
Jimi Olaghere is one of the first patients to have been functionally cured of sickle cell disease with a CRISPR gene-edited cell therapy.
Ep158: David Younger and Randolph Lopez on SynBio & AI for Discovery
David Younger and Randolph Lopez, co-founders of A-Alpha Bio, on using synthetic biology and AI to discover new biologic drugs.
Ep157: Vineeta Agarwala of A16Z on Investing in AI for Drug Discovery
Vineeta Agarwala, general partner at A16Z's Bio & Health fund, on investing in AI for drug discovery.
Ep156: David Liu on New Tools and Techniques for Biology
David Liu, professor of chemistry at Harvard University and co-founder of multiple biotech companies, including Beam Therapeutics and Prime Medicine.
Ep155: Valerie Daggett on Early Detection, and Treatment, of Alzheimer's
Valerie Daggett, founder and CEO of Seattle-based AltPep, on early detection and treatment of Alzheimer's.
Ep154: Robert Ang on CRISPR to Protect Bone Marrow & Attack Cancer
Robert Ang, CEO of Cambridge, Mass.-based Vor Bio, on using CRISPR gene editing to alter bone marrow transplants and improve treatment of acute myeloid leukemia.
Ep153: Rick Young on Studying Gene Expression for Drug Discovery
Rick Young, professor at MIT and co-founder of Syros Pharmaceuticals, CAMP4 Therapeutics, Omega Therapeutics, and Dewpoint Therapeutics, on studying gene expression for drug discovery.
